Perhexiline (maleate) (Standard)

Perhexiline (maleate) (Standard) is the analytical standard of Perhexiline (maleate) . This product is intended for research and analytical applications. Perhexiline maleate is an orally active CPT1 and CPT2 inhibitor that reduces fatty acid metabolism. Perhexiline maleate induces mitochondrial dysfunction and apoptosis in hepatic cells. Perhexiline maleate can cross the blood brain barrier (BBB) and shows anti-tumor activity. Perhexiline maleate can be used in the research of cancers, and cardiovascular disease like angina[1][2][5].

Product Specifications

CAS Number

[6724-53-4]

UNSPSC

12352100

Target

Apoptosis; Mitochondrial Metabolism; Reference Standards

Related Pathways

Apoptosis; Metabolic Enzyme/Protease; Others

Field of Research

Cancer; Cardiovascular Disease

Smiles

O=C(O)/C=C\C(O)=O.C1(CC(C2CCCCC2)C3CCCCC3)NCCCC1

Molecular Formula

C23H39NO4

Molecular Weight

393.56

References & Citations

[1]E. Marc Jolicoeur, et al. 27 - Refractory Angina. Chronic Coronary Artery Disease, 2018, 412-431. |[2]Zhen Ren, et al. Mitochondrial dysfunction and apoptosis underlie the hepatotoxicity of perhexiline. Toxicol In Vitro. 2020 Dec;69:104987. |[3]P-P Liu, et al. Elimination of chronic lymphocytic leukemia cells in stromal microenvironment by targeting CPT with an antiangina drug perhexiline. Oncogene. 2016 Oct 27;35 (43) :5663-5673. |[4]Giovanni Licari, et al. Enantioselectivity in the tissue distribution of perhexiline contributes to different effects on hepatic histology and peripheral neural function in rats. Pharmacol Res Perspect. 2018 Jun;6 (3) :e00406. |[5]Shiva Kant, et al. Perhexiline Demonstrates FYN-mediated Antitumor Activity in Glioblastoma. Mol Cancer Ther. 2020 Jul;19 (7) :1415-1422.